How the cinchona tree makes quinine - solved after a century of effort

Quinine has one of the longest resumes in pharmaceutical history. For over 350 years, it was the only effective treatment for malaria - a disease caused by Plasmodium parasites transmitted by Anopheles mosquitoes that continues to kill hundreds of thousands of people annually. Quinine remains in clinical use today across tropical Central Africa, where malaria is still a common cause of illness and death. Its chemical relative quinidine treats cardiac arrhythmia. The broader family of cinchona alkaloids serves as catalysts in numerous industrial chemical processes, generating an estimated $2 billion in annual economic value worldwide.

All of it still comes from tree bark. Every gram of industrial quinine is extracted from the bark of cinchona trees grown on large-scale tropical plantations, then purified through a multi-step chemical process. Despite more than a hundred years of dedicated scientific effort, no one had managed to identify the complete set of enzymatic steps the tree uses to build these complex molecules from simple precursors.

A study published by the Max Planck Institute for Chemical Ecology in Jena, Germany, has now filled in those missing enzymatic steps - and in the process discovered enzymes performing chemical reactions that no one expected them to catalyze.

From Quechua bark to an unsolved biochemical puzzle

The cinchona tree (Cinchona spp.) takes its name from the Quechua term quina-quina, meaning "bark of barks" - a name reflecting the compound's South American origins and its reputation among indigenous peoples long before European contact. Powdered quina-quina bark was likely brought to Europe by Jesuit missionaries in the 17th century as an effective fever remedy. By the early 19th century, European chemists had isolated quinine as the active ingredient, making it one of the first pure active compounds ever extracted from a natural source and arguably the first true chemotherapeutic agent in the modern pharmaceutical sense.

Jena itself has a notable historical connection to quinine research. In 1908, the chemist Paul Rabe first described quinine's complete molecular structure at Friedrich Schiller University, located just down the road from where the biosynthetic pathway was finally completed more than a century later.

The difficulty of solving the pathway reflected several compounding problems that stymied researchers generation after generation. Cinchona alkaloids possess an unusual and complex chemical structure with no close analogues in well-characterized plant metabolic systems, making it difficult to use comparisons with known pathways as a guide. The intermediate compounds between starting materials and final products were largely unknown, which made it impossible to predict what types of enzymes might be involved at each step. Analytical methods for detecting these intermediates were inadequate until recently. And the red cinchona tree itself proved notoriously difficult to cultivate under controlled greenhouse and sterile laboratory conditions necessary for metabolic studies.

Following labeled molecules through living tissue

The research team, led by Sarah O'Connor, director at the Max Planck Institute and head of the Department of Natural Product Biosynthesis, tackled the problem with the systematic thoroughness of chemical detective work. Lead authors Blaise Kimbadi Lombe, a postdoctoral researcher originally from the Democratic Republic of the Congo, and doctoral student Tingan Zhou designed experiments to trace the pathway from known starting points to known end products, identifying everything in between.

Previous work in the Jena group had identified the first portion of the metabolic pathway and established corynantheal as a key intermediate compound. Further experiments had demonstrated that the cinchona tree converts corynantheal into the final alkaloid products. But the precise mechanism of that conversion - which chemical transformations occurred, in what order, and catalyzed by which specific enzymes - remained completely unknown.

To map the missing steps, the researchers fed isotopically labeled precursor molecules to the leaves, stems, and roots of living red cinchona trees (Cinchona pubescens) and then tracked where the isotopic labels appeared in downstream metabolic products. This approach - essentially following a molecular tag through the plant's biochemical machinery - identified three previously unknown intermediate products that represented critical missing pieces of the biosynthetic puzzle.

A transferase that performs an unexpected ring closure

Using gene expression data from different plant tissues, protein analysis, and evolutionary comparisons with related plant species, the team identified the first two enzymes in the newly revealed segment of the pathway. These enzymes produce a newly discovered intermediate called malonyl-corynantheol. To confirm that this compound was genuinely part of the quinine production pathway rather than an unrelated metabolic byproduct, the researchers used gene silencing techniques to temporarily shut down the genes encoding these enzymes. Without them, production of quinine and other cinchona alkaloids collapsed - definitive confirmation that malonyl-corynantheol is a true biosynthetic precursor.

The most challenging step was identifying the enzyme responsible for converting malonyl-corynantheol into the next intermediate, which the team named cinchonium. After many unsuccessful attempts using conventional candidate gene approaches, the researchers succeeded by integrating gene activity profiles, protein expression data, and evolutionary gene patterns across multiple plant species and tissue types simultaneously.

The result delivered a genuine surprise. Based on its amino acid sequence, the protein clearly belonged to the transferase enzyme family - a large class of enzymes that typically transfer chemical functional groups from one molecule to another. But this particular transferase was catalyzing a cyclization reaction, closing a ring in the molecular structure of its substrate. That is fundamentally not what transferases are known or expected to do. The discovery expands the known catalytic repertoire of this enzyme family and serves as a reminder that enzyme function cannot always be reliably predicted from sequence alone.

Building the scaffold that defines all cinchona alkaloids

From the cinchonium intermediate, the team showed that two additional enzymes catalyze the final structural transformations. These reactions accomplish a remarkable feat of molecular architecture: expanding the molecule's indole ring system into a quinoline ring system to produce the quinoline-quinuclidine scaffold - the defining structural motif shared by all cinchona alkaloids, including quinine, quinidine, and their derivatives.

The two enzymes responsible for this transformation belong to unrelated protein families - an oxoglutarate-dependent dioxygenase and a cytochrome P450 oxidase - that collaborate on a shared structural objective through sequential catalytic steps. This kind of enzymatic collaboration between evolutionarily unrelated enzyme families is a hallmark of complex natural product pathways and one reason they are so difficult to reconstruct through prediction alone.

With the complete enzymatic toolkit in hand, the research team demonstrated two practical capabilities. First, they could produce known medicinal cinchona alkaloids in laboratory conditions using the identified enzymes. Second, they could generate structural derivatives - analogue compounds that do not occur naturally in cinchona bark but could potentially be explored for novel medicinal properties or improved catalytic applications.

From plantations to bioreactors - eventually

Currently, all industrial quinine production depends entirely on extraction from cinchona bark harvested from plantations in tropical regions. The process is resource-intensive, geographically constrained to equatorial growing zones, and subject to agricultural variability from weather, disease, and land-use competition. Knowing the complete enzymatic pathway opens the long-discussed possibility of producing these compounds through synthetic biology approaches - engineering microorganisms such as yeast or bacteria to manufacture cinchona alkaloids in controlled bioreactor conditions independent of agricultural supply chains.

Similar biosynthetic approaches have already been demonstrated successfully for other complex plant natural products, including the antimalarial artemisinin and the opioid precursor thebaine. The cinchona pathway is arguably more structurally complex than either of these precedents, but the existence of successful models suggests the approach is technically feasible given sufficient engineering effort.

The gap between pathway knowledge and industrial production

Identifying the enzymes in a plant and successfully reconstituting the complete multi-step pathway in a microbial production host are fundamentally different technical challenges. Enzyme activity levels in foreign host organisms are often far lower than in the native plant. Cofactor availability, substrate channeling between sequential enzymes, and the potential toxicity of pathway intermediates to the host organism can all create production bottlenecks that require extensive engineering to overcome. The step from proof of concept to commercially viable industrial-scale biosynthetic production routinely takes a decade or more of optimization work.

The study also focused specifically on the red cinchona tree. Whether the same enzymatic steps operate identically in other Cinchona species - some of which produce different ratios and proportions of the various alkaloids - has not been fully established. Variations in enzyme specificity, expression levels, or regulatory mechanisms across species could affect how broadly and directly these particular findings can be applied.

There is also a socioeconomic dimension that deserves consideration alongside the scientific achievement. Cinchona plantations support agricultural communities in tropical regions of South America, Africa, and Southeast Asia. A successful shift to biotechnological production in industrial bioreactors would carry significant economic consequences for those farming communities - a consideration that tends to receive less attention in biosynthetic research publications but matters considerably in the real-world implementation of the technology.